trial · primary record
Leriglitazone
Adrenoleukodystrophy
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 116 |
| Primary completion | 2025-03-06 |
| Primary endpoint | Part 1: Change from baseline to Week 96 in the total distance walked (meters) in the 6-minute walk test |
| Registry ID | NCT03231878 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:43:09.920Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03231878
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.